Who Paid My Doc
Ryanodex
Drug Hyperthermic Condition
NDC 42367-540-32
General payments
$110,969
Research payments
$916,773
Through program year 2024, $110,969 in general payments and $916,773 in research payments were reported against Ryanodex (Hyperthermic Condition).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $1,472 | 18 |
| 2023 | General | $4,849 | 204 |
| 2022 | General | $2,262 | 109 |
| 2021 | General | $6,516 | 173 |
| 2021 | Research | $402,101 | 9 |
| 2020 | General | $30,707 | 52 |
| 2020 | Research | $378,024 | 8 |
| 2019 | General | $65,162 | 58 |
| 2019 | Research | $136,647 | 5 |
Breakdown
The top 5 of 18 recipients; each share is of general payments naming this product in 2024.
The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 9 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
614 general · 22 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.